Many Clinically Stable CIDP Patients Can Safely Stop IVIG Maintenance Treatment
While intravenous immune globulin (IVIG) therapy is efficacious for patients with chronic inflammatory demyelinating polyneuropathy (CIDP), the lack of biomarkers for disease activity makes the need for ongoing treatment difficult to assess.
Addition of Eltrombopag Improves Efficacy of Standard Therapy for Aplastic Anemia
Eltrombopay found to improve therapy for aplastic anemia.
IG Treatment May Reduce Acute Exacerbations of COPD
Observational studies suggest immune globulin (IG) treatment may reduce the frequency of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
IVIG Plus Glucocorticoids Effective for Treating COVID-19 Pediatric Syndrome
A large multicenter clinical trial has found intravenous immune globulin (IVIG) plus glucocorticoids may be better than IVIG alone for treating multisystem inflammatory syndrome in children (MIS-C) caused by COVID-19.
Kedrion to Market RYPLAZIM to Treat Rare Disease
Kedrion Biopharma is now marketing and distributing RYPLAZIM (plasminogen human-tvmh) in the United States to treat C-PLGD.
FDA Approves Avacopan to Treat Rare Autoimmune Disease
The U.S. Food and Drug Administration (FDA) has approved Chemo- Centryx Inc.’s Avacopan, sold under the brand name Tavneos, to treat antineutrophil cytoplasmic antibody-associated vasculitides.
The Current Challenge of Immune Globulin Access
Understanding the factors contributing to the current shortage of immune globulin could help to address a crisis that threatens dire consequences for patients.
Importing Drugs: Is It Safe and Responsible?
As Americans continue to grapple with the skyrocketing costs of prescription drugs, many are turning to other countries to access medications they need at prices they can afford.
Stable and Durable Factor VIII Expression in Subjects Dosed with Investigational Hemophilia A Gene Therapy
More than two years after receiving Spark Therapeutics’ investigational adeno-associated virus (AAV)-mediated gene therapy (SPK-8011), five adult subjects with hemophilia A exhibited stable factor VIII (FVIII) expression, with no evidence of FVIII inhibitors or a cellular immune response.
Breakthroughs in Stem Cell Research
Optimism continues to grow about the use of stem cells in regenerative medicine highlighted by hundreds of successful clinical trials.
